Titan Partners Group Expands Research Capabilities with Healthcare Expert Dr. Boris Peaker
TL;DR
Titan Partners gains a competitive edge with the launch of Equity Research Division led by Dr. Peaker in healthcare biotechnology.
Equity Research Division launched by Titan Partners, appoints Dr. Peaker as managing director for healthcare sector research.
Titan Partners' focus on strong and compelling stories in healthcare with Dr. Peaker's experience aims to benefit the industry and investors.
Learn about Titan Partners' new Equity Research Division and Dr. Peaker's appointment in the healthcare biotechnology sector.
Found this article helpful?
Share it with your network and spread the knowledge!
Titan Partners Group, a division of American Capital Partners, has launched its Equity Research Division by appointing Dr. Boris Peaker as managing director and senior equity research analyst. Dr. Peaker brings 17 years of specialized experience in healthcare equity research, with a particular focus on the biotechnology sector.
Jason Sands, co-founder and partner at Titan, highlighted the strategic significance of this appointment, emphasizing the firm's commitment to building research capabilities around fundamentally strong and scientifically compelling investment narratives. Dr. Peaker's extensive background and reputation in healthcare equity research align closely with Titan's strategic objectives.
The addition of a dedicated equity research platform represents a significant milestone for Titan Partners Group. By bringing Dr. Peaker on board, the firm is positioning itself to provide more sophisticated and targeted research insights in the healthcare and biotechnology domains.
This expansion signals Titan's intention to strengthen its investment banking services and offer more comprehensive advisory solutions to emerging growth companies. The new research division is expected to enhance the firm's ability to identify and analyze investment opportunities in complex and innovative sectors.
Curated from InvestorBrandNetwork (IBN)
